RavenQuest Partner McGill University Secures Cannabis License
NR19-20 September 26, 2019
September 26, 2019 – Vancouver, British Columbia – RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest” - https://www.youtube.com/watch?v=UgUsP8r2KiA&t=9s ), one of Canada’s most innovative cannabis producers, is pleased to announce that its research partner, McGill University, has received a license from Health Canada which allows for the possession and production of cannabis for research purposes.
The license allows RavenQuest and McGill to continue important research around the cannabis plant. The research continues to focus on cultivar recognition, plant stabilization, yield maximization and disease resistance of the cannabis plant.
RavenQuest CEO, George Robinson, commented that “throughout our partnership with McGill, research has thus far uncovered several key beneficial microbes which have shown significant potential to improve yield and disease resistance. The Health Canada license will allow RavenQuest and McGill to confirm our findings by applying the microbes directly to the cannabis plant.”
“RavenQuest’s foundation is grounded in science and innovation. As a company, we have always maintained that large scale Cannabis producers need to develop non-GMO methods to produce genetically consistent, disease resistant and biologically stable plant material that will meet pharmaceutical standards for clinicians to conduct medical research trials. With the granting of this license, the research we are conducting with our partners at McGill moves us even closer toward that end” Robinson continued.
For more information, access RavenQuest’s investor presentation, fact sheet and videos here.